Skip to main content

Bottneuro advancing personalized Alzheimer’s therapy

| News

Bottneuro advancing personalized Alzheimer’s therapy


Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of a patient’s brain are stimulated. In order to determine the correct areas of the brain for treatment, the spin-off from the University of Basel has turned to the imaging processes developed by Positrigo.

Three co-founders of Bottneuro: Bekim Osmani, Tino Töpper and Alois C. Hopf (img: Bottneuro)

One approach to treating Alzheimer’s disease is to eliminate substances that cause the disease by stimulating specific areas of the brain. This is the strategy being pursued by the startup Bottneuro, a spin-off from the University of Basel based at Technologiepark Basel. The company intends to establish a network of diagnostic centers for Alzheimer’s patients to offer personalized therapy approaches to those affected by the disease. The business magazine Forbes listed Bottneuro among the 30 best spin-offs situated in the German-speaking DACH (Germany, Austria and Switzerland) region to keep an eye on over the course of 2021.

For the development of its personalized therapy, Bottneuro is joining forces with Positrigo. The spin-off from the Swiss Federal Institute of Technology Zurich (ETH) specializes in the development of nuclear medicine imaging technologies. Bottneuro is planning to use a positron emission tomography (PET) device developed by Positrigo to accurately localize the correct areas of the brain to treat in Alzheimer’s patients.

The two startups have signed a Memorandum of Understanding (MoU) for the delivery of several NeuroLF-type brain PET imaging devices, Positrigo writes in a press release. These are to be delivered as soon as a CE mark is awarded to the NeuroLF. “We are delighted to agree this cooperation with Positrigo”, comments Bekim Osmani, Managing Director of Bottneuro, in the press release. “The NeuroLF brain PET device will enable us to offer cost-effective PET scans in our Alzheimer’s diagnostic centers in order to obtain important 3D data sets that we need for our personalized Alzheimer’s therapy”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.